Gonca Ozcan Dannehy, MD
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Lymphoma and Myeloma, Cancer Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Istanbul University Istanbul School of Medicine, Istanbul, Istanbul Province, TR, General Medicine, Doctor of Medicine |
Postgraduate Training
| 2023-2026 | Hematology - Medical Oncology Fellowship, National Heart Lung and Blood Institute, Bethesda, Maryland |
| 2021-2022 | Clinical and Translational Science Certificate Program, University of Connecticut Health Center, Farmington, Connecticut |
| 2020-2023 | Internal Medicine Residency, University of Connecticut Health Center, Farmington, Connecticut |
Licenses & Certifications
| null | Texas Medical Board |
| null | American Board of Internal Medicine - Medical Oncology |
| null | American Board of Internal Medicine |
| null | AHA Cardiac Life Support Certification |
| null | D.C. Board of Medicine - MD and DO |
Experience & Service
Administrative Appointments/Responsibilities
Member, American Society of Clinical Oncology, Alexandria, Virginia, 2026 - Present
Alumni Relations Co-Chair, NIH, Bethesda, Maryland, 2025 - 2026
Member, NCI, Bethesda, Maryland, 2024 - 2026
Other Professional Positions
Research Assistant, Bone Marrow Transplantation and Cellular Therapy Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2020
Honors & Awards
| 2025 | Elaine M. Sloand Award for Excellence in Hematology, NIH Hematology/Oncology Fellowship |
| 2025 | SOHO Young Investigator Travel Award, Society of Hematologic Oncology |
| 2025 | Women in Cancer Immunotherapy Network, Society for Immunotherapy of Cancer |
| 2025 | FDA/ASCO Fellows' Day Workshop, American Society of Clinical Oncology |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2024. HIT or not HIT? NHLBI Hematology Interdisciplinary Grand Rounds & Hematology Consult Service. Invited.
- 2023. Current Landscape of CAR-T Therapies in Solid Tumors: Advances and Challenges. Invited. NCI/NHLBI Hematology Fellowship Faculty & Fellows Conference. Bethesda, Maryland, US.
- 2023. Current Landscape of Amyloidosis. Invited. Clinical Pathology Conferences, Grand Rounds. Hartford, Connecticut, US.
Selected Publications
Other Articles
- Gordan MJ, Cho-Wosoba H, Ozcan G, Lakhotia R, Hill E, Melani C, Wilson W Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma. Blood Adv 10(16):5694-5697, 2026. PMID: 42341324.
- Ozcan G, Roswarski JL, Dunleavy K SOHO State of the Art Updates and Next Questions. Clin Lymphoma Myeloma Leuk, 2026. PMID: 42603756.
- Ozcan G, Roschewski M SOHO State of the Art Updates and Next Questions. Clin Lymphoma Myeloma Leuk 26(4):200-208, 2026. PMID: 41763974.
- Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial J, Chen G, Kadia T, Short NJ, Daver NG, Kantarjian H, Marin D, Kebriaei P, Popat U, Champlin R, Shpall E, Oran B TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Adv 9(11):2845-2854, 2025. PMID: 39853269.
- Fein JA, McAuliffe A, Fischer K, Brady O, Devlin SM, Willumsen S, Ozcan G, Montanaro P, Pristyazhnyuk Y, DiGiuseppe J, Lahoud OB, Perales M, Pfister DG, Giralt S, Dailey M, Yu PP, Sauter CS A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation. Leuk Lymphoma 66(4):713-720, 2024. PMID: 39641218.
- Becker EC, Ozcan G, Wu GY Primary Hepatic Extra-gastrointestinal Stromal Tumors. J Clin Transl Hepatol 11(4):942-948, 2023. PMID: 37408818.
- Ozcan G, Gautam G, Cunha TD, Becker EC, Perosevic N Peritoneal Carcinomatosis as an Initial Presentation of Gastrointestinal Stromal Tumor: A Case Report and Review of the Literature. Cureus 14(6), 2022. PMID: 35785012.
- Ozcan G, Shaikh A, Becker E, Perosevic N Not a Statin-Induced Myopathy: Metastatic Pancreatic Adenocarcinoma Presenting As Paraneoplastic Myositis. Cureus 14(5):e26421, 2022. PMID: 35591892.
- Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14):e142116, 2021. PMID: 34138753.
- Mohammed T, Ozcan G, Siddique A, Araneta R, Slater D, Khan A Doege-Potter Syndrome with a Benign Solitary Fibrous Tumor: A Case Report and Literature Review. Case Rep Oncol 14(1):470-476, 2021. PMID: 33976622.
- Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. PMID: 32902645.
- Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. PMID: 32717029.
- Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. PMID: 31821460.
Abstracts
- Ozcan G, Cook L, Lakhotia R, Wilson W, Ng S, Melani C, Rocco J, Gordon M. Dynamic changes in peripheral blood immune cells are associated with response to targeted therapies in relapsed/refractory T-cell lymphoma. AACR 7(3 Suppl), 2026. e-Pub 2026.
- Perez CO, Ozcan G, Pathan S, Gava F, Goel S, Kochenderfer JN, Shah N, Rocco J, Doran S. Retrospective Analysis of Cytomegalovirus Infections In Recipients of Chimeric Antigen Receptor T-cell Therapy 32(3 Suppl):S12-S13, 2026. e-Pub 2026.
- Ozcan G, Lakhotia R, Melani C, Gordon MJ, Muppidi JR, Pittaluga S, Phelan JD, Ramsower C, Rimsza LM, Robertorye RS, Wright G, Meerson M, Postovalova E, Bagaev A, Fowler N, Lindenberg L, Mena E, Bergvall E, Tadese A, Evans S, Rochewski M. IBCL-1106: Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma: A Phase 2 Study 25(Supplement 1):S834-S835, 2025. e-Pub 2025.
- Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era 140(Supplement 1):10620-10621, 2022. e-Pub 2022. PMID: 2.
- Ozcan G, Braish J, Mohammed TJ, Hong C, Mott N, Eanniella M, Shahrokni A, Salner AL, Yu PP, Nipp RD, Elias R. Home-based geriatric oncology care: A feasibility study. 2022 ASCO Quality Care Symp 40(28 Suppl), 2022. e-Pub 2022.
- Fein JA, McAuliffe A, Fischer K, Brady O, Devlin SM, Willumsen S, Ozcan G, Montanaro P, Pristyazhnyuk Y, DiGiuseppe J, Lahoud OB, Perales MA, Pfister DG, Giralt S, Dailey M, Yu PP, Sauter CS. Impact of a shared-care model between community and academic centers for facilitating access to allogeneic and autologous stem cell transplantation. 2022 ASCO Quality Care Symp, 2022. e-Pub 2022.
- Ozcan G, Hundal J, Da Cunha T, Grover D, Perosevic N. A rare cause of upper gastrointestinal bleeding - Gastric neuroendocrine tumor. Society of General Internal Medicine 37(Suppl), 2022. e-Pub 2022.
- Gautam G, Ozcan G, Parikh R. Case of coagulopathy in liver disease. Society of General Internal Medicine 37(Suppl), 2022. e-Pub 2022.
- Gautam G, Ozcan G, Perosevic N. Interesting case of vision impairment due to neuromyelitis optica. Society of General Internal Medicine 37(Suppl), 2022. e-Pub 2022.
- Ozcan G, Gautam G, Perosevic N. Burkitt's lymphoma is waiting on the corner. Society of General Internal Medicine 37(Suppl), 2022. e-Pub 2022.
- Ozcan G, Gautam G, Perosevic N. Myeloid Sarcoma-A very rare entity not to be forgotten. Society of General Internal Medicine 37(Suppl), 2022. e-Pub 2022.
- Kumar S, Kulkarni RB, Ozcan G, Tipirneni A, Vankina R, and Baker JW. An evaluation of patient workflow in hematology clinics at a university hospital referred for the workup of monoclonal gammopathy of undetermined significance (MGUS). 2021 ASCO Quality Care Symposium 39(28 Suppl):207-207, 2021. e-Pub 2021.
- Ozcan G, Perosevic N. Not a statin-induced myopathy. Society of General Internal Medicine 36(1 Suppl), 2021. e-Pub 2021.
- Ozcan G, Hadfield M, Perosevic N. When the Liver Goes Bad, Life Goes Sad- Severe Resistant Hepatic Encephalopathy Due to Fibrolamellar Hepatic Cancer. American Thoracic Society 2021 International Conference 203(Suppl 1):A4935, 2021. e-Pub 2021.
- Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman AS, Mendt MC, Kerbauy L, Shanley M, Ozcan G, Ensley E, Nunez Cortes AK, Li L, Lu J, Kaplan M, Nandivada V, Bdaiwi M, Li Y, Garcia LM, Liu E, Ang S, Banerjee PP, Champlin RE, Shpall EJ, Rezvani K. Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. Blood 134(Suppl 1):1944, 2019. e-Pub 2019.
- Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Mendt MC, Kerbauy L, Shanley M, Nunez Cortes AK, Li L, Banerjee PP, Mohanty V, Lu J, Ozcan G, Ensley E, Nandivada V, Kaplan M, Bdaiwi MH, Liu E, Ang S, Chen K, Konopleva MY, Champlin RE, Shpall EJ, Rezvani K. Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies. Blood 134(Suppl 1):1936, 2019. e-Pub 2019.
- Basar R, Daher M, Uprety N, Gokdemir ED, Vilchez MCM, Ozcan G, Shanley M. Combining CD5-Targeted Chimeric Antigen Receptor Engineering and Genetic Editing of TGF-BR2 for the Treatment of T-Cell Hematologic Malignancies. Molecular Therapy:4-17, 2019. e-Pub 2019.
- Ozcan G. Combination targeted therapy with venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide (ViPOR) in relapsed/refractory diffuse large B-cell (DLBCL): Long-term follow-up of safety, efficacy, and B-cell recovery. ASH.
Book Chapters
- Ozcan Dannehy G, Singh M, Mortensen E. Subject adherence:. In: In Handbook for Designing and Conducting Clinical and Translational Research, Translational Radiation Oncology. Academic Press, 437-443, 2023.
- Ozcan Dannehy G, Singh M, Mortensen E. Surveys and questionnaires:. In: In Handbook for Designing and Conducting Clinical and Translational Research, Translational Radiation Oncology. Academic Press, 283-290, 2023.
Patient Reviews
CV information above last modified October 05, 2026